Pharmacogenetics of colorectal cancer.
Colorectal cancer is one of the most common types of cancer in both men and women. Multiple chemotherapy combinations exist; however, there is currently no strategy for individualised therapy selection prior to treatment. Genetic polymorphisms in genes involved in the metabolism, transport or targets for the commonly used chemotherapy drugs (5-fluorouracil, irinotecan and oxaliplatin) have been described. Many require validation in large prospective trials before they can be used as markers for outcome and/or toxicity. This review describes the data available on polymorphisms in key genes that are associated with chemotherapy toxicity and response in colorectal cancer.
Marsh
Sharon
S
Division of Oncology, Washington University School of Medicine, 660 South Euclid Ave, Campus Box 8069, St Louis, MO 63110, USA. smarsh@im.wustl.edu
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*
D000970:Antineoplastic Agents